Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma
- PMID: 20683678
- DOI: 10.1007/s12029-010-9194-4
Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma
Abstract
Introduction: Treatment options for advanced hepatocellular cancer (HCC) are limited. Sorafenib, an orally active multi-kinase inhibitor, is the only systemic agent with a survival benefit in randomized studies. However, the gain in survival is modest and new treatment strategies are needed.
Clinical cases: We report two cases of advanced HCC treated with a combination of sorafenib and radiation therapy. Impressive and sustained clinical and radiological responses were seen. Treatment was well-tolerated in both cases with no unexpected toxicities reported.
Discussion: There is sound rationale for the combination of sorafenib and radiation therapy for treatment of HCC. These two cases suggest both feasibility and efficacy of this combination, in selected patients. Prospective studies addressing this combination are ongoing.
Similar articles
-
Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.Radiat Oncol. 2010 Feb 12;5:12. doi: 10.1186/1748-717X-5-12. Radiat Oncol. 2010. PMID: 20149262 Free PMC article. Clinical Trial.
-
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.Nat Rev Clin Oncol. 2009 Sep;6(9):505-6. doi: 10.1038/nrclinonc.2009.114. Nat Rev Clin Oncol. 2009. PMID: 19707242 No abstract available.
-
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].BMC Cancer. 2008 Nov 26;8:349. doi: 10.1186/1471-2407-8-349. BMC Cancer. 2008. PMID: 19036146 Free PMC article. Clinical Trial.
-
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Oncology (Williston Park). 2011. PMID: 21548473 Review.
-
[Sorafenib and radiotherapy association for hepatocellular carcinoma].Cancer Radiother. 2011 Feb;15(1):77-80. doi: 10.1016/j.canrad.2010.11.012. Epub 2011 Jan 15. Cancer Radiother. 2011. PMID: 21239203 Review. French.
Cited by
-
Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters.Sci Rep. 2020 Jun 12;10(1):9575. doi: 10.1038/s41598-020-66583-9. Sci Rep. 2020. PMID: 32533042 Free PMC article.
-
A new Prenylated Flavonoid induces G0/G1 arrest and apoptosis through p38/JNK MAPK pathways in Human Hepatocellular Carcinoma cells.Sci Rep. 2017 Jul 18;7(1):5736. doi: 10.1038/s41598-017-05955-0. Sci Rep. 2017. PMID: 28720813 Free PMC article.
-
Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study.Sci Rep. 2021 Jan 15;11(1):1614. doi: 10.1038/s41598-021-81176-w. Sci Rep. 2021. PMID: 33452421 Free PMC article.
-
Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.J Natl Cancer Inst. 2016 Jul 4;108(9):djw133. doi: 10.1093/jnci/djw133. Print 2016 Sep. J Natl Cancer Inst. 2016. PMID: 27377923 Free PMC article. Review.
-
Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression.PLoS One. 2014 Sep 17;9(9):e107149. doi: 10.1371/journal.pone.0107149. eCollection 2014. PLoS One. 2014. PMID: 25229655 Free PMC article.